LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Sage Therapeutics Inc

Затворен

СекторЗдравеопазване

9.17 -0.97

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

9.16

Максимум

9.27

Ключови измерители

By Trading Economics

Приходи

34M

-62M

Продажби

1.2M

14M

EPS

-0.998

Марж на печалбата

-442.395

Служители

353

EBITDA

13M

-67M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

-4.53% downside

Дивиденти

By Dow Jones

Следващи печалби

30.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

96M

582M

Предишно отваряне

10.14

Предишно затваряне

9.17

Настроения в новините

By Acuity

100%

0%

364 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Sage Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.06.2025 г., 20:51 ч. UTC

Печалби

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

27.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

27.06.2025 г., 20:48 ч. UTC

Пазарно говорене

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27.06.2025 г., 20:46 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

27.06.2025 г., 20:46 ч. UTC

Пазарно говорене

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27.06.2025 г., 19:31 ч. UTC

Пазарно говорене

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27.06.2025 г., 19:19 ч. UTC

Пазарно говорене

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27.06.2025 г., 19:16 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27.06.2025 г., 18:42 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.06.2025 г., 18:42 ч. UTC

Пазарно говорене

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27.06.2025 г., 18:39 ч. UTC

Пазарно говорене
Печалби

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27.06.2025 г., 18:29 ч. UTC

Пазарно говорене

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27.06.2025 г., 18:18 ч. UTC

Пазарно говорене

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27.06.2025 г., 18:16 ч. UTC

Пазарно говорене

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27.06.2025 г., 17:16 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27.06.2025 г., 17:08 ч. UTC

Печалби

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27.06.2025 г., 16:52 ч. UTC

Придобивния, сливания и поглъщания

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27.06.2025 г., 16:22 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

27.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

27.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

27.06.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

27.06.2025 г., 15:59 ч. UTC

Пазарно говорене

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27.06.2025 г., 15:56 ч. UTC

Пазарно говорене

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Sage Therapeutics Inc Прогноза

Ценова цел

By TipRanks

-4.53% надолу

12-месечна прогноза

Среден 8.86 USD  -4.53%

Висок 12 USD

Нисък 5 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за Sage Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

15 ratings

1

Купи

13

Задържане

1

Продай

Техническа оценка

By Trading Central

N/A / 7.285Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Neutral Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Sage Therapeutics Inc

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.